COMMUNIQUÉS West-GlobeNewswire

Imprivata Enterprise Access Management Wins 2026 Best in KLAS Award for Access Management
04/02/2026
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Imprivata , a leading provider of access management solutions for healthcare and other mission-critical industries, today announced that Imprivata Enterprise Access [...]
New Study Finds Use of Psychiatric Collaborative Care Model Has Expanded Rapidly for Children and Adults, but With Enormous Disparities Among States
04/02/2026
Key organizations call on 14 state Medicaid agencies to reimburse for CoCM to improve patient outcomes and reduce total healthcare costs for Medicaid, Medicare and commercial plans WASHINGTON, Feb. 04, 2026 (GLOBE [...]
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]
Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026
04/02/2026
GARDEN CITY, N.Y., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors and [...]
SAB BIO to Participate in Upcoming Investor Conferences
04/02/2026
MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
R1 Awarded ‘Best in KLAS’ Across Multiple RCM Categories for 2026
04/02/2026
Providers Recognize R1 for Unwavering Commitment to Launching Innovative Technology CHICAGO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), the leader in healthcare revenue management, has been named a [...]
Breckenridge Distillery Appoints Romano Beverage for Distribution in Illinois
04/02/2026
Award-winning spirits brand announce new distribution partner to oversee statewide distribution BRECKENRIDGE, Colo., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and [...]
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
04/02/2026
PRINCETON, N.J., Feb. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
04/02/2026
Results Support TAMP’s Novel Approach to Targeted, Pressure-Mediated Chemotherapeutic Delivery and Reinforces its Potential to Provide Individualized, Optimized Drug-Delivery MOUNTAIN VIEW, Calif., Feb. 04, 2026 (GLOBE [...]
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced [...]
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
04/02/2026
This is the third program that s uccessfully combine s Entera’s oral peptide N- Tab ® platform with OPKO ’s advanced protein chemistry capabilities The c ompanies have accelerated this program and aim to file an [...]
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
04/02/2026
February 4, 2026 Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models Cardiff, UK – [...]
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
04/02/2026
Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 mg nusinersen The high-dose regimen of [...]
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company
04/02/2026
T he Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted EBITDA Raanana, [...]
CytomX Therapeutics to Present at Upcoming February Conferences
04/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will [...]
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
04/02/2026
Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051 DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” [...]
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
04/02/2026
NAARDEN, The Netherlands and MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
Cannara annonce un placement privé stratégique sans intermédiaire de 6,3 millions $ CA au prix de 2,10 $ CA par action ordinaire
04/02/2026
MONTRÉAL, 04 févr. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », « la Société », « nous » ou « notre ») ( TSXV : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis de [...]
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
04/02/2026
Real-world and clinical trial data underscore long-term safety and effectiveness in pediatric and adult NPC patients CELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra [...]

Pages